MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.canlet.2026.218434

Медицинская библиотека · Cancer letters · 2026

Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma.

Sang Chen, Rao Dongning, Qin Haokai, Zhang Mao, Luo Rongkui, Huang Yingying, Pan Jiaomeng, Lin Youpei, Zhang Shu, Lin Jian, Gao Qiang

СтатьяПеревод в очереди

Аннотация

Intrahepatic cholangiocarcinoma (iCCA), a highly lethal subtype of liver cancer with increasing incidence and poor prognosis, displays profound molecular heterogeneity that limits therapeutic efficacy. Combining multi-omics with pathological subtyping in iCCA, we identified a strong association between the most aggressive molecular subtype and the large-duct pathological type, characterized by aberrant mucin overexpression and prominent myeloid cell infiltration. Through integrative analysis, MUC16 was identified as a key molecular marker specifically enriched in large-duct type intrahepatic cholangiocarcinoma (L-iCCA). Functional modulation of MUC16 markedly inhibited L-iCCA cell proliferation and migration. Furthermore, high-throughput drug screening identified the small-molecule compound OSMI-1 as a potent suppressor of MUC16 expression. Using primary iCCA cell lines and patient-derived organoids (PDOs), we confirmed that OSMI-1 inhibits L-iCCA cell proliferation and migration by downregulating MUC16. Mechanistically, OSMI-1 suppresses MUC16 expression by disrupting the transcriptional complex formed between OGT and IRF1. Employing a genetically engineered L-iCCA mouse model, we further validated the crucial role of MUC16 in tumor progression and neutrophil infiltration, demonstrated that OSMI-1 synergized with gemcitabine, effectively inhibiting L-iCCA growth. This study presents a pathological subtype-based precision therapeutic strategy for L-iCCA, thereby providing a foundation for novel translational approaches to the personalized management of this disease.

Для цитирования: Sang Chen, Rao Dongning, Qin Haokai, Zhang Mao, Luo Rongkui, Huang Yingying, Pan Jiaomeng, Lin Youpei, Zhang Shu, Lin Jian, Gao Qiang. Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma.. Cancer letters. 2026. DOI: 10.1016/j.canlet.2026.218434.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.